Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Elkins David V

Short Bartie Wendy

Bristol Myers Squibb offers an attractive 4.5% dividend yield, well above market averages. While the company faces patent expirations on key drugs like Revlimid and Eliquis, its strong financial position, reasonable 72% payout ratio, investment-grade credit rating, and decades-long dividend history suggest the dividend is likely safe for most investors.

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Bristol Myers Squibb has maintained an 18-year dividend growth streak despite facing patent cliffs on flagship drugs like Eliquis. The company's $3.5 billion in planned cost savings by 2027 and a sustainable 40% payout ratio support continued dividend growth. With $10.5 billion in cash reserves, BMY appears well-positioned to maintain and grow its 4.5% dividend yield.

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The company plans to submit a New Drug Application to the FDA this fiscal year, with peak annual sales potential of $3-6 billion.

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Nxera Pharma has joined OpenFold, a non-profit AI research consortium for drug discovery, alongside major pharmaceutical and technology companies including Bristol Myers Squibb, Novo Nordisk, Bayer, Roche, AWS, Microsoft, and NVIDIA. The participation aligns with Nxera's strategy to enhance R&D productivity through AI technologies and leverage its NxWave™ GPCR drug discovery platform with open-source structural prediction models.

Bristol-Myers Squibb Company (BMY) Stock Price, Analysis & Trade Signals